Human Genome's arthritis drug is effective

trial of LymphoStat-B in patients with rheumatoid arthritis showing the efficacy of the treatment in this patient group.A total of 283 patients participated in the phase II study designed to evaluate the safety, optimal dosing and efficacy of LymphoStat-B (belimuma) in patients with active moderate-to-severe rheumatoid arthritis who had failed prior treatment(s).